SCHEMBL30830888

SCHEMBL30830888

CN1C[C@H](Nc2cnn(C)c(=O)c2Cl)C[C@H](c2ccc(C(=O)N3CCC4(CC3)CCN(c3cccc5c3C(=O)N(C3CCC(=O)NC3=O)C5=O)CC4)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 9/20 0.48
▸ BRD9 Q9H8M2 3/20 0.48
▸ CRBN Q96SW2 4/20 0.43
▸ HPGDS O60760 2/20 0.43
▸ DDB1 Q16531 2/20 0.39
▸ BRD1 O95696 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ BRPF1 P55201 1/20 0.39
▸ BPTF Q12830 1/20 0.39
▸ KAT2A Q92830 1/20 0.39
▸ BRD7 Q9NPI1 1/20 0.39
▸ BAZ2B Q9UIF8 1/20 0.39
▸ BRPF3 Q9ULD4 1/20 0.39
▸ MAP1LC3B Q9GZQ8 5/20 0.38
▸ EP300 Q09472 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830953 0.93 KAT2B (0.48) KAT2BBRD9CRBNHPGDSDDB1
SCHEMBL30830482 0.89 KAT2B (0.48) KAT2BBRD9CRBNHPGDSDDB1
SCHEMBL30830616 0.89 KAT2B (0.51) KAT2BBRD9CRBNHPGDSDDB1
SCHEMBL30830926 0.88 AR (0.48) KAT2BBRD9CRBNHPGDSBRD1
SCHEMBL30830793 0.86 CRBN (0.50) KAT2BBRD9CRBNHPGDSDDB1
SCHEMBL30830945 0.85 KAT2B (0.49) KAT2BBRD9CRBNHPGDSDDB1
SCHEMBL30830835 0.84 KAT2B (0.49) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830473 0.84 KAT2B (0.51) KAT2BBRD9CRBNHPGDSBRD1
SCHEMBL30831074 0.83 KAT2B (0.51) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830776 0.83 KAT2B (0.51) KAT2BBRD9BRD1ACHEBRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback